The human nervous system, intricately woven into every aspect of our existence, falls prey to a vast array of neurological disorders.
These conditions--Alzheimer's disease, Parkinson's disease, multiple sclerosis, and countless others--manifest in a multitude of ways, impacting movement, speech, cognition, and beyond. Complications associated with these disorders can be devastating, ranging from memory loss and tumors to seizures, paralysis, and even coma. The sheer complexity of the nervous system and the often-intertwined mechanisms of these disorders pose significant challenges in diagnosis, treatment, and finding cures.
Identifying and employing neurologically relevant and disease-specific biomarkers are critical not only in drug discovery, drug development, and clinical trials, but also in clinical practice--for accurate diagnosis & prognosis and to establish a recommended course of treatment. Biomarker variability based on demography, race, and ethnicity should also be considered when designing appropriate assay panels.
Scalable and sensitive assays that accurately detect early markers are crucial for the early detection of neurological disorders, most of which are irreversible. Developing assays designed with reagents that account for the biological intricacies of biomarkers is critical to advance research and properly diagnose and predict neurological disease. Faced with the challenges of understanding the mechanism of action of even the most prevalent neurological disorders, it is important to employ a broad spectrum of relevant biomarker panels and sensitive assays.
Multiple Sclerosis (MS)
IgG index and albumin
IFN-Beta
sIL-2R
P-tau
NF-light
sILNAR2
Alzheimer's Disease (AD)
Beta Amyloid: Aβ38, Aβ40, Aβ42, Aβ43, 6E10
Tau Protein: P-tau181, 217, 231
Others: NF-light, GFAP, sTREM2, YKL-40, Neurogranin, APOE4, UCH-L1
Parkinson's Disease (PD)
α-synuclein
DJ-1
EGFR
Apo-A1
Peripheral inflammatory markers: IL-8, IL-6
Other Neurodegenerative Diseases
NF-light
Neurogranin
NPTX2
Cognitive Decline: Neurogranin, BACE1, P-tau, EGF
Biomarker Services at PBL Assay Science
PBL has decades of experience developing and running immunoassays and offers a diverse range of singleplex and multiplex biomarker assays on multiple platforms. We offer our own assays, we qualify third-party assays, and we develop new assays for our clients. Our flexibility and client-centric approach are essential for researchers interested in investigating novel biomarkers or improving upon the utility of commercially available assays. Lean On Us to expedite your clinical studies and internal R&D efforts in the neurologicial disease space.

Let's Discuss Your Project